Health and wellness platform Hims & Hers Health Inc (NYSE:HIMS) announced on Thursday that it has launched access to generic semaglutide through its platform in Canada, marking its first international generic GLP-1 offering.

The company said that personalised treatment plans will start at CAD149 per month to improve affordability and access.

Nearly two-thirds of Canadian adults are overweight or living with obesity, with cost identified as a key barrier to treatment access. Through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include generic semaglutide or branded options, supported by ongoing Care Team access and lifestyle resources covering nutrition, movement, and sleep.

Generic semaglutide is authorised by Health Canada for Type 2 diabetes management and may be prescribed off-label for weight management at a provider's discretion. Hims & Hers Canada Inc does not currently offer access to treatment services for Type 2 diabetes.

The launch supports the company's broader international expansion strategy and reflects efforts to address evolving GLP-1 market dynamics.